Chemomab Therapeutics (CMMB) Return on Capital Employed (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Return on Capital Employed came in at 8636860.89% in Q4 2025, up 623630451.0% YoY from N/an in Q4 2024, and up 142.98% on a QoQ basis from 3554495.55% in Q3 2025.
Chemomab Therapeutics (CMMB) Return on Capital Employed (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Return on Capital Employed data on file, last reported at 8636860.89% in Q4 2025.
- Quarterly Return on Capital Employed rose 623630451.0% year-over-year to 8636860.89% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8636860.89% (up 623630451.0% YoY) and the FY2025 annual result came in at 293.77%, up 10849.0% from the prior year.
- Return on Capital Employed grew to 8636860.89% in Q4 2025, from 3554495.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8636860.89% in Q4 2025 to a low of 35.91% in Q1 2021.
- A 5-year average of 810819.82% and a median of 261.7% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 6998 bps — and 2025, when it soared 623630451 bps.
- Tracing CMMB's Return on Capital Employed over 5 years: stood at 37.24% in 2021, then surged by 298 bps to 148.32% in 2022, then jumped by 154 bps to 377.19% in 2023, then surged by 636335 bps to 2400556.38% in 2024, then jumped by 260 bps to 8636860.89% in 2025.
- The last three Return on Capital Employed figures came in at 8636860.89% (Q4 2025), 3554495.55% (Q3 2025), and 2400556.38% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 8,636,050.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,636,860.89% |
| Sep 30, 2025 | 3,554,495.55% |
| Dec 31, 2024 | 2,400,556.38% |
| Sep 30, 2024 | 432.79% |
| Jun 30, 2024 | 488.98% |
| Mar 31, 2024 | 400.64% |
| Dec 31, 2023 | 377.19% |
| Sep 30, 2023 | 338.39% |
| Jun 30, 2023 | 295.57% |
| Mar 31, 2023 | 227.84% |
| Dec 31, 2022 | 148.32% |
| Sep 30, 2022 | 85.12% |
| Jun 30, 2022 | 54.64% |
| Mar 31, 2022 | 34.08% |
| Dec 31, 2021 | 37.24% |
| Sep 30, 2021 | -20.16% |
| Jun 30, 2021 | -20.68% |
| Mar 31, 2021 | -35.91% |
| Dec 31, 2020 | -129.61% |
| Sep 30, 2020 | -1,044.06% |